Evidence map›Paper›PMID 34200207›Full record

ArticleGenes2021

Genetic Risk Profiling Associated with Recurrent Unprovoked Venous Thromboembolism.

Hossam Hodeib, Amira Youssef, Alzahraa A Allam, Amal Selim, Mohamed A Tawfik, Mohammed F Abosamak, Ahmed Esam, Mohamed S Abd Elghafar, Sameh Samir, Ola A ELshora

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Genes, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Hossam HodeibClinical Pathology Department, Faculty of Medicine, Tanta University, Tanta 31512, Egypt.
Amira YoussefClinical Pathology Department, Faculty of Medicine, Tanta University, Tanta 31512, Egypt.
Alzahraa A AllamInternal Medicine Department, Faculty of Medicine, Tanta University, Tanta 31512, Egypt.
Amal SelimInternal Medicine Department, Faculty of Medicine, Tanta University, Tanta 31512, Egypt.
Mohamed A TawfikInternal Medicine Department, Faculty of Medicine, Tanta University, Tanta 31512, Egypt.ORCID 0000-0002-8200-0535
Mohammed F AbosamakAnesthesia/ICU Department, Faculty of Medicine, Tanta University Hospital, Tanta 31512, Egypt.ORCID 0000-0002-1412-304X
Ahmed EsamAnesthesia/ICU Department, Faculty of Medicine, Tanta University Hospital, Tanta 31512, Egypt.
Mohamed S Abd ElghafarAnesthesia/ICU Department, Faculty of Medicine, Tanta University Hospital, Tanta 31512, Egypt.
Sameh SamirCardiovascular Medicine Department, Faculty of Medicine, Tanta University, Tanta 31511, Egypt.
Ola A ELshoraClinical Pathology Department, Faculty of Medicine, Tanta University, Tanta 31512, Egypt.
Tanta University · EGTanta University Hospital · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionVenous thromboembolism (VTE), including deep vein thrombosis (DVT) and/or pulmonary embolism (PE), is a common, acute, multifactorial disease with a five-years cumulative incidence of recurrence of approximately 25%. Actually, no single genetic defect can predict the risk of recurrence of VTE. Therefore, individual genetic risk profiling could be useful for the prediction of VTE recurrence. AIM OF THE STUDY: To assess the combined effect of the common prothrombotic genotypes on the risk of recurrence of VTE in recently diagnosed unprovoked VTE patients. PATIENTS AND

methodsThis population based, prospective follow-up study was carried out from January 2015 to December 2020 in (internal medicine, cardiovascular medicine and anesthesia and ICU departments, Tanta University Hospital, Egypt) on 224 recently diagnosed unprovoked VTE patients. Whole blood was collected by standard venipuncture at the time of admission prior to the beginning of anticoagulant therapy. Genomic DNA was extracted and was genotyped for the 5-SNPs Genetic risk score (GRS), previously validated for first venous thrombosis (FVL rs6025, PTM rs1799963, ABO rs8176719, FGG rs2066865 and FXI rs2036914).

resultsThe main important finding in the present study was that patients having ≥3 risk alleles were associated with higher risk of VTE recurrence compared to those having ≤2 risk alleles (the reference group) (HR 2.5, 95% CI 1.48-4.21) (

conclusionGRS model could be an effective and useful model in risk stratification of VTE patients, and genetic risk profiling of VTE patients could be used for the prediction of recurrence of VTE.

Indexed as

Polymorphism, Single NucleotideABO Blood-Group SystemAdultAgedBlood Coagulation FactorsFemaleGalactosyltransferasesHumansMaleMiddle AgedVenous ThromboembolismABO Blood-Group SystemABO protein, humanBlood Coagulation FactorsGalactosyltransferasesgenetic risk scorevenous thromboembolism

Identifiers

PMID34200207
PMCPMC8230078
OpenAlexW3172685676

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.